Loading
MST-0312 is an experimental bispecific agonist antibody from Mestag Therapeutics, in phase 1 trials for advanced solid tumours.
MST-0312 is a bispecific agonist antibody from Mestag Therapeutics. A FAP-targeted bispecific antibody that activates the lymphotoxin-beta receptor (LTBR) in the tumour, to induce tertiary lymphoid structures and high endothelial venules that help the immune system attack the tumour. Its furthest stage is phase 1, for advanced solid tumours (initially non-small cell lung cancer, melanoma, bladder cancer, colorectal cancer and triple-negative breast cancer). ClinicalTrials.gov registers it in one study linked below. STARLYS phase 1 NCT07610941 recruiting; first patient dosed per release of 19 May 2026. Whether it works in people has not been established unless a trial below reports it.
A FAP-targeted bispecific antibody that activates the lymphotoxin-beta receptor (LTBR) in the tumour, to induce tertiary lymphoid structures and high endothelial venules that help the immune system attack the tumour. Connects to FAP.
1.One arm of MST-0312 binds FAP on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MST-0312" OR ABSTRACT:"MST-0312") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MST-0312, not a curated reading list.
Shares FAP and the tag pipeline.
Shares FAP and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/